| Drug Name |
Methotrexate |
| Drug ID |
BADD_D01418 |
| Description |
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis.[A180322] This inhibition leads to suppression of inflammation as well as prevention of cell division.[A180322] Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180]
Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments.[L7180]
Methotrexate was granted FDA approval on 7 December 1953.[L7198] |
| Indications and Usage |
Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis. Methotrexate is indicated in the management of selected adults with severe, active rheumatoid arthritis (ACR criteria), or children with active polyarticular-course juvenile rheumatoid arthritis. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L01BA01; L04AX03 |
| DrugBank ID |
DB00563
|
| KEGG ID |
D00142
|
| MeSH ID |
D008727
|
| PubChem ID |
126941
|
| TTD Drug ID |
D0SV8E
|
| NDC Product Code |
59137-530; 0703-3671; 59137-550; 0703-3678; 52652-2001; 0143-9516; 0143-9830; 61703-408; 69238-1423; 51285-367; 49452-4601; 66220-812; 66220-810; 0143-9519; 70518-1398; 0143-9517; 61703-350; 16729-277; 66220-822; 54436-012; 59137-535; 59137-540; 59137-510; 70771-1058; 54436-022; 70518-3263; 66220-817; 59137-520; 0703-3675; 54436-020; 51407-121; 51079-670; 71335-1772; 58623-0040; 0143-9367; 46014-1005; 50090-5457; 71335-0782; 42291-505; 59137-525; 0143-9518; 46014-1023; 0904-7141; 51285-369; 51927-1565; 54436-025; 0378-0014; 68382-775; 66220-815; 71335-1118; 59651-182; 66220-820; 59137-505; 59137-515; 63660-0006; 12780-0491; 51285-366; 66220-825; 54436-017; 46014-1133; 66220-807; 51285-368; 16729-486; 54436-010; 0555-0572; 54436-015; 50268-527 |
| Synonyms |
Methotrexate | Amethopterin | Methotrexate, (D)-Isomer | Methotrexate, (DL)-Isomer | Mexate | Methotrexate Sodium | Sodium, Methotrexate | Methotrexate, Sodium Salt | Methotrexate, Disodium Salt | Methotrexate Hydrate | Hydrate, Methotrexate | Methotrexate, Dicesium Salt | Dicesium Salt Methotrexate |
